Antibodies to SARS-CoV-2 and risk of past or future sick leave

Abstract The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. We invited all employees (n = 15,300) at work at the Karolinska University Hospital, Stockholm, Sweden to participate in a study examining SARS-Cov-2 antibodies in relation to registered...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Joakim Dillner, K. Miriam Elfström, Jonas Blomqvist, Carina Eklund, Camilla Lagheden, Sara Nordqvist-Kleppe, Cecilia Hellström, Jennie Olofsson, Eni Andersson, August Jernbom Falk, Sofia Bergström, Emilie Hultin, Elisa Pin, Anna Månberg, Peter Nilsson, My Hedhammar, Sophia Hober, Johan Mattsson, Laila Sara Arroyo Mühr, Kalle Conneryd Lundgren
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
R
Q
Acceso en línea:https://doaj.org/article/a12aa03869c945dba2214b88c4d4805c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Abstract The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. We invited all employees (n = 15,300) at work at the Karolinska University Hospital, Stockholm, Sweden to participate in a study examining SARS-Cov-2 antibodies in relation to registered sick leave. For consenting 12,928 healthy hospital employees antibodies to SARS-CoV-2 could be determined and compared to participant sick leave records. Subjects with viral serum antibodies were not at excess risk for future sick leave (adjusted odds ratio (OR) controlling for age and sex: 0.85 [95% confidence interval (CI) (0.85 (0.43–1.68)]. By contrast, subjects with antibodies had an excess risk for sick leave in the weeks prior to testing [adjusted OR in multivariate analysis: 3.34 (2.98–3.74)]. Thus, presence of viral antibodies marks past disease and protection against excess risk of future disease. Knowledge of whether exposed subjects have had disease in the past or are at risk for future disease is essential for planning of control measures. Trial registration: First registered on 02/06/20, ClinicalTrials.gov NCT04411576.